Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and
ROS1. In a safety database trial, it was suggested an association of Crizotinib
with the development of renal cyst in patients with non-small-cell lung cancer
(NSCLC). Aim: To report an uncommon side effect of Crizotinib in a patient with
NSLC. Case Presentation: We report the case of a 68-year-old woman with NSCLC
who developed bilateral progressive aseptic renal abscesses during Crizotinib
treatment. Conclusion: Further studies may be necessary to determinate the risk
of renal cyst development and the management of these complications.
References
[1]
Soda, M., Choi, Y.L., Enomoto, M., et al. (2007) Identification of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. Nature, 448, 561-566. http://dx.doi.org/10.1038/nature05945
[2]
Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. (2010) Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. New England Journal of Medicine, 363, 1693-1703. http://dx.doi.org/10.1056/NEJMoa1006448
[3]
Kutok, J.L. and Aster, J.C. (2002) Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 20, 3691-3702. http://dx.doi.org/10.1056/NEJMoa1006448
[4]
George, R.E., Sanda, T., Hanna, M., et al. (2008) Activating Mutations in ALK Provide a Therapeutic Target in Neuroblastoma. Nature, 455, 975-978. http://dx.doi.org/10.1038/nature07397
[5]
Wong, D.W., Leung, E.L., So, K.K., et al. (2009) The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers from Nonsmokers with Wild-Type EGFR and KRAS. Cancer, 115, 1723-1733. http://dx.doi.org/10.1002/cncr.24181
[6]
Ou, S.H., Kwak, E.L., Siwak-Tapp, C., et al. (2011) Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-Small Cell Lung Cancer Patient with de novo MET Amplification. Journal of Thoracic Oncology, 6, 942-946. http://dx.doi.org/10.1097/JTO.0b013e31821528d3
[7]
Bergethon, K., Shaw, A.T., Ou, S.H., et al. (2012) ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. Journal of Clinical Oncology, 30, 863-870. http://dx.doi.org/10.1200/JCO.2011.35.6345
[8]
Solomon, B.J., Mok, T., Kim, D.W., et al. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371, 2167-2177. http://dx.doi.org/10.1056/NEJMoa1408440
[9]
Shaw, A.T., Kim, D.W., Nakagawa, K., et al. (2013) Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 368, 2385-2394. http://dx.doi.org/10.1056/NEJMoa1214886
[10]
Camidge, D.R., Bang, Y.J., Kwak, E.L., et al. (2012) Activity and Safety of Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Updated Results from a Phase 1 Study. Lancet Oncology, 13, 1011-1019. http://dx.doi.org/10.1016/s1470-2045(12)70344-3
[11]
Kim, D.W., Ahn, M.J., Shi, Y., et al. (2012) Results of a Global Phase II Study with Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 30, Abstract 7533.
[12]
Schnell, P., Bartlett, C.H., Solomon, B.J., Tassell, V., Shaw, A.T., de Pas, T., et al. (2015) Complex Renal Cysts Associated with Crizotinib Treatment. Cancer Medicine, 4, 887-896. http://dx.doi.org/10.1002/cam4.437
[13]
XALKORI U.S. Physician Prescribing Information. Accessed 15 May 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=676
[14]
Lin, Y.-T., Wang, Y.-F., Yang, J.C., Yu, C.-J., Wu, S.-G., Shih, J.-Y. and Yang, P.-C. (2014) Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 9, 1720-1725. http://dx.doi.org/10.1097/JTO.0000000000000326
[15]
Klempner, S.J., Aubin, G., Dash, A. and Ou, S.H. (2014) Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts during Continuous Crizotinib Treatment. Oncologist, 19, 1008-1010. http://dx.doi.org/10.1634/theoncologist.2014-0216
[16]
Yoneshima, Y., Okamoto, I., Arimura-Omori, M., Kimura, S., Hidaka-Fujimoto, N., Iwama, E., Harada, T., Takayama, K. and Nakanishi, Y. (2015) Infected Complex Renal Cysts during Crizotinib Therapy in a Patient with Non-Small Cell Lung Cancer Positive for ALK Rearrangement. Investigational New Drugs, 33, 510-512. http://dx.doi.org/10.1007/s10637-014-0195-1
